Greater Noida(Business Desk): Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its un-audited Financial Result for the first Quarter of FY26 ended 30th June 2025.
Q1 FY26 CONSOLIDATED FINANCIAL HIGHLIGHTS
For Q1FY26, Regulated Markets Revenue stood at Rs 90 crs, growing by 69% Y-o-Y. EBIDTA Margin for Regulated Markets business stood at 35.5% in Q1 FY26.
- For Q1 FY26, Emerging Markets Revenue stood at Rs. 29 crs, growing by 32% Y-o-Y. EBIDTA Margin for Emerging Markets business stood at 6% in Q1 FY26.
- In the Regulated Markets the company currently has:
- 24 Own commercial products
- 70 Approved ANDA products
- 57 Pipeline products with 37 CGT opportunity products
- 27 CDMO/CMO commercial products
- 53 CDMO/CMO pipeline products
For the Emerging Markets the company currently has:
- 308 Registered products
- 719 products under Registration
- Presence across more than 40 countries
Commenting on the results, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said, “Continuing the momentum from last year, we have started FY26 well, with healthy
performance across segments during the quarter.
We launched 2 own ANDA products in the Regulated Markets during the quarter. We also received the ANDA approval for 4 products during the quarter. We have a strong pipeline in place which we will launch over the next couple of years. Our moat lies in our ability to serve the government channel in addition to the retail channel in the US. This gives us considerable competitive advantage in the US market. A large part of our product pipeline has potential to cater to the government contracts. Our capability to manufacture and supply controlled
substances in US is another differentiator for us.
Our CDMO / CMO segment is also scaling up as planned. We are adding new contracts and increasing the share of pocket from existing customers. The contracts in hand give us good visibility for the year ahead. With respect to the US tariff situation, we believe we are largely insulated with our entire formulation manufacturing happening locally in US.
In the Emerging Markets, our changing product portfolio and go-to-market strategies are resulting in improved profitability.
Our Branded Generics segment is witnessing significant uptick in momentum. On the back of increasing field force, our monthly revenue run rate has more than doubled versus last year. We expect to be a pan-India player by the end of FY26.
We are also pleased to report positive Operating Cash Flow of Rs 11 crores for Q1FY26. We expect to sustain and build on the cash flow trajectory going forward.
Our business is undergoing a structural advancement which will provide better market visibility and support the growth momentum for us over the medium term to longer term. We will continue to drive the business on three key pillars – (i) Expansion of the ANDA Portfolio in Regulated Markets; (ii) Steady Scale-up of the CDMO/CMO Segment in Regulated Markets; and (iii) Portfolio Expansion and Profitability Improvement in Emerging Markets”
